Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Diabetes. 2019 Jan;68(1):3-14. doi: 10.2337/dbi18-0035.
My scientific career has focused on understanding the mechanisms underlying insulin resistance with the goal of developing new strategies to prevent and treat type 2 diabetes. My early studies focused on understanding how insulin promotes glucose transport into adipocytes, a classic model of highly insulin-responsive target cells. When we found changes in adipocyte glucose transport in altered metabolic states, we were highly motivated to understand the consequences of this on whole-body glucose homeostasis. In the late 1980s, when GLUT4, the major insulin-regulated glucose transporter, was identified, my lab observed that it was downregulated in adipocytes but not in skeletal muscle in insulin-resistant states, such as obesity and type 2 diabetes, in humans and rodents. We investigated the role of GLUT4 in adipose tissue and muscle in whole-body insulin sensitivity, making tissue-specific GLUT4-overexpressing and GLUT4 knockout mice. These studies led to the discovery that adipocytes, and specifically glucose transport into adipocytes, regulate whole-body glucose homeostasis. As adipocytes take up relatively little glucose, we investigated the underlying mechanisms. In the 1990s, we performed DNA microarrays on adipose tissue from adipose-specific GLUT4-overexpressing and GLUT4 knockout mice to find reciprocally regulated genes, and we identified several molecules that were not previously known to regulate systemic insulin sensitivity and/or energy balance. More recently, with Alan Saghatelian's lab, we discovered a novel class of lipids with antidiabetes and anti-inflammatory effects. We also investigated the effects of the adipose-secreted hormone, leptin, on insulin sensitivity. We found that the AMP-activated protein kinase (AMPK) pathway mediates leptin's effects on fatty acid oxidation in muscle and also plays a role in leptin's anorexigenic effects in the hypothalamus. These studies transformed AMPK from a "fuel gauge" that regulates energy supply at the cellular level to a sensing and signaling pathway that regulates organismal energy balance. Overall, these studies have expanded our understanding of the multifaceted role of adipose tissue in metabolic health and how adipose dysfunction increases the risk for type 2 diabetes.
我的科研生涯专注于研究胰岛素抵抗的作用机制,旨在寻找预防和治疗 2 型糖尿病的新策略。我的早期研究集中于了解胰岛素如何促进葡萄糖进入脂肪细胞的转运,脂肪细胞是胰岛素高度敏感的典型靶细胞。当我们发现代谢状态改变时脂肪细胞葡萄糖转运发生变化,我们非常希望了解这对全身葡萄糖稳态的影响。上世纪 80 年代末,当 GLUT4(主要的胰岛素调节葡萄糖转运蛋白)被鉴定出来时,我的实验室观察到,在肥胖和 2 型糖尿病等胰岛素抵抗状态下,GLUT4 在脂肪细胞中被下调,但在骨骼肌中没有下调。我们研究了 GLUT4 在脂肪组织和肌肉中的作用,构建了组织特异性 GLUT4 过表达和 GLUT4 敲除小鼠。这些研究发现,脂肪细胞,特别是葡萄糖进入脂肪细胞的转运,调节全身葡萄糖稳态。由于脂肪细胞摄取的葡萄糖相对较少,我们研究了其潜在机制。上世纪 90 年代,我们对脂肪特异性 GLUT4 过表达和 GLUT4 敲除小鼠的脂肪组织进行了 DNA 微阵列分析,以寻找相互调节的基因,并发现了一些以前未知的调节全身胰岛素敏感性和/或能量平衡的分子。最近,与 Alan Saghatelian 的实验室合作,我们发现了一类具有抗糖尿病和抗炎作用的新型脂质。我们还研究了脂肪分泌激素瘦素对胰岛素敏感性的影响。我们发现,AMP 激活蛋白激酶(AMPK)通路介导了瘦素对肌肉脂肪酸氧化的作用,也在瘦素对下丘脑的厌食作用中发挥作用。这些研究将 AMPK 从调节细胞水平能量供应的“燃料计”转变为调节机体能量平衡的感应和信号通路。总的来说,这些研究扩展了我们对脂肪组织在代谢健康中的多方面作用的理解,以及脂肪功能障碍如何增加 2 型糖尿病的风险。